Home300601 • SHE
add
Shenzhen Kangtai Biological Prods Co Ltd
Previous close
¥16.79
Year range
¥13.10 - ¥21.39
Market cap
18.38B CNY
Avg Volume
19.63M
P/E ratio
338.37
Dividend yield
0.54%
Primary exchange
SHE
Market news
Financials
Income Statement
Revenue
Net income
| (CNY) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 746.86M | -0.47% |
Operating expense | 545.63M | 14.03% |
Net income | 15.10M | -86.43% |
Net profit margin | 2.02 | -86.38% |
Earnings per share | — | — |
EBITDA | 41.21M | -73.10% |
Effective tax rate | 156.17% | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.44B | 221.80% |
Total assets | 14.13B | -2.19% |
Total liabilities | 4.53B | -7.75% |
Total equity | 9.60B | — |
Shares outstanding | 1.12B | — |
Price to book | 1.95 | — |
Return on assets | -1.00% | — |
Return on capital | -1.23% | — |
Cash Flow
Net change in cash
| (CNY) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 15.10M | -86.43% |
Cash from operations | 121.90M | -8.83% |
Cash from investing | 62.96M | -23.54% |
Cash from financing | -187.09M | 75.28% |
Net change in cash | -2.37M | 99.56% |
Free cash flow | 2.56B | 636.57% |
About
Shenzhen Kangtai Biological Products, also known as BioKangtai, is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China. Wikipedia
Founded
Sep 8, 1992
Website
Employees
1,913
